Our future studies will focus on circulating tumor-derived exosomal HMGA2 as a plasma-based biomarker for noninvasive screening of patients for NPC metastases, along with testing targeted therapies aimed at blocking HMGA2 to halt metastasis. This evidence concerns the gene HMGA2 and nasopharyngeal carcinoma.